Pharmacologic treatments for covid-19 patients

C1 Esterase/Kallikrein Inhibitor vs Standard care

This comparison will not be updated. Last search date 28 Feb, 2022.


Hospitalized patients

Forest plots
(last update: 2020-11-20)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=55

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
RBR-5s2mqg
Mansour E, medRxiv, 2020
Full text
Commentary
Public/non profit

Icatibant

C1 Esterase/Kallikrein Inhibitor

Icatibant

Standard care

Standard care

C1 Esterase/Kallikrein Inhibitor

RCT Patients with COVID-19 (severe) admitted to a single center in Brazil N=30
Some concerns
Details

Full description